Loading…

Safety of Novel Microbes for Human Consumption: Practical Examples of Assessment in the European Union

Novel microbes are either newly isolated genera and species from natural sources or bacterial strains derived from existing bacteria. Novel microbes are gaining increasing attention for the general aims to preserve and modify foods and to modulate gut microbiota. The use of novel microbes to improve...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in microbiology 2017-09, Vol.8, p.1725-1725
Main Authors: Brodmann, Theodor, Endo, Akihito, Gueimonde, Miguel, Vinderola, Gabriel, Kneifel, Wolfgang, de Vos, Willem M, Salminen, Seppo, Gómez-Gallego, Carlos
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c579t-75e51cbffbd387455307c592c904cd687df7c219b4e18a7e333b30d01de6283b3
cites cdi_FETCH-LOGICAL-c579t-75e51cbffbd387455307c592c904cd687df7c219b4e18a7e333b30d01de6283b3
container_end_page 1725
container_issue
container_start_page 1725
container_title Frontiers in microbiology
container_volume 8
creator Brodmann, Theodor
Endo, Akihito
Gueimonde, Miguel
Vinderola, Gabriel
Kneifel, Wolfgang
de Vos, Willem M
Salminen, Seppo
Gómez-Gallego, Carlos
description Novel microbes are either newly isolated genera and species from natural sources or bacterial strains derived from existing bacteria. Novel microbes are gaining increasing attention for the general aims to preserve and modify foods and to modulate gut microbiota. The use of novel microbes to improve health outcomes is of particular interest because growing evidence points to the importance of gut microbiota in human health. As well, some recently isolated microorganisms have promise for use as probiotics, although in-depth assessment of their safety is necessary. Recent examples of microorganisms calling for more detailed evaluation include , fructophilic lactic acid bacteria (FLAB), and . This paper discusses each candidate's safety evaluation for novel food or novel food ingredient approval according to European Union (EU) regulations. The factors evaluated include their beneficial properties, antibiotic resistance profiling, history of safe use (if available), publication of the genomic sequence, toxicological studies in agreement with novel food regulations, and the qualified presumptions of safety. Sufficient evidences have made possible to support and authorize the use of heat-inactivated in the European Union. In the case of , the discussion focuses on earlier safety studies and the strain's suitability. FLAB are also subjected to standard safety assessments, which, along with their proximity to lactic acid bacteria generally considered to be safe, may lead to novel food authorization in the future. Further research with will increase knowledge about its safety and probiotic properties and may lead to its future use as novel food. Upcoming changes in EUU Regulation 2015/2283 on novel food will facilitate the authorization of future novel products and might increase the presence of novel microbes in the food market.
doi_str_mv 10.3389/fmicb.2017.01725
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_29dcec8ce79347808b22cb12ae2d4359</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_29dcec8ce79347808b22cb12ae2d4359</doaj_id><sourcerecordid>1944440956</sourcerecordid><originalsourceid>FETCH-LOGICAL-c579t-75e51cbffbd387455307c592c904cd687df7c219b4e18a7e333b30d01de6283b3</originalsourceid><addsrcrecordid>eNpVUk1r3DAQNaWlCWnuPRUde9mtPizLyqEQlk0TSNJCG-hNSPJ4oyBLrmQnzb-vdjcNyYBmBmnemwd6VfWR4CVjrfzSD86aJcVELMuh_E11SJqmXjBMf7990R9Uxznf4RI1piW_rw5oKzlnhBxW_U_dw_SIYo-u4z14dOVsigYy6mNC5_OgA1rFkOdhnFwMJ-hH0nZyVnu0_quH0ZfJgj3NGXIeIEzIBTTdAlrPKY5Q0Deh4D5U73rtMxw_1aPq5mz9a3W-uPz-7WJ1ermwXMhpIThwYk3fm461oi4asbBcUitxbbumFV0vLCXS1EBaLYAxZhjuMOmgoW3pj6qLPW8X9Z0akxt0elRRO7W7iGmjdCryPSgqOwu2tSAkq0WLW0OpNYRqoF3NuCxcJ3uuB72B4EJJKuhkXd4RemfSlvxhTir4bRlnkxWngu_AX_fgcjlA2RSmpP0rRa9fgrtVm3iveIMJbupC8PmJIMU_M-RJDS5b8F4HiHNWRNYlsORNGcX70fJzOSfon9cQrLZWUTurqK1V1M4qBfLppbxnwH9jsH834r2O</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1944440956</pqid></control><display><type>article</type><title>Safety of Novel Microbes for Human Consumption: Practical Examples of Assessment in the European Union</title><source>Open Access: PubMed Central</source><creator>Brodmann, Theodor ; Endo, Akihito ; Gueimonde, Miguel ; Vinderola, Gabriel ; Kneifel, Wolfgang ; de Vos, Willem M ; Salminen, Seppo ; Gómez-Gallego, Carlos</creator><creatorcontrib>Brodmann, Theodor ; Endo, Akihito ; Gueimonde, Miguel ; Vinderola, Gabriel ; Kneifel, Wolfgang ; de Vos, Willem M ; Salminen, Seppo ; Gómez-Gallego, Carlos</creatorcontrib><description>Novel microbes are either newly isolated genera and species from natural sources or bacterial strains derived from existing bacteria. Novel microbes are gaining increasing attention for the general aims to preserve and modify foods and to modulate gut microbiota. The use of novel microbes to improve health outcomes is of particular interest because growing evidence points to the importance of gut microbiota in human health. As well, some recently isolated microorganisms have promise for use as probiotics, although in-depth assessment of their safety is necessary. Recent examples of microorganisms calling for more detailed evaluation include , fructophilic lactic acid bacteria (FLAB), and . This paper discusses each candidate's safety evaluation for novel food or novel food ingredient approval according to European Union (EU) regulations. The factors evaluated include their beneficial properties, antibiotic resistance profiling, history of safe use (if available), publication of the genomic sequence, toxicological studies in agreement with novel food regulations, and the qualified presumptions of safety. Sufficient evidences have made possible to support and authorize the use of heat-inactivated in the European Union. In the case of , the discussion focuses on earlier safety studies and the strain's suitability. FLAB are also subjected to standard safety assessments, which, along with their proximity to lactic acid bacteria generally considered to be safe, may lead to novel food authorization in the future. Further research with will increase knowledge about its safety and probiotic properties and may lead to its future use as novel food. Upcoming changes in EUU Regulation 2015/2283 on novel food will facilitate the authorization of future novel products and might increase the presence of novel microbes in the food market.</description><identifier>ISSN: 1664-302X</identifier><identifier>EISSN: 1664-302X</identifier><identifier>DOI: 10.3389/fmicb.2017.01725</identifier><identifier>PMID: 28955311</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Akkermansia muciniphila ; Bacteroides xylanisolvens ; Faecalibacterium prausnitzii ; fructophilic lactic acid bacteria ; Fructophilic lactic acid bacteria, Faecalibacterium prausnitzii ; Microbiology ; Novel microbes ; Safety</subject><ispartof>Frontiers in microbiology, 2017-09, Vol.8, p.1725-1725</ispartof><rights>Copyright © 2017 Brodmann, Endo, Gueimonde, Vinderola, Kneifel, de Vos, Salminen and Gómez-Gallego. 2017 Brodmann, Endo, Gueimonde, Vinderola, Kneifel, de Vos, Salminen and Gómez-Gallego</rights><rights>Wageningen University &amp; Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c579t-75e51cbffbd387455307c592c904cd687df7c219b4e18a7e333b30d01de6283b3</citedby><cites>FETCH-LOGICAL-c579t-75e51cbffbd387455307c592c904cd687df7c219b4e18a7e333b30d01de6283b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601064/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601064/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28955311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brodmann, Theodor</creatorcontrib><creatorcontrib>Endo, Akihito</creatorcontrib><creatorcontrib>Gueimonde, Miguel</creatorcontrib><creatorcontrib>Vinderola, Gabriel</creatorcontrib><creatorcontrib>Kneifel, Wolfgang</creatorcontrib><creatorcontrib>de Vos, Willem M</creatorcontrib><creatorcontrib>Salminen, Seppo</creatorcontrib><creatorcontrib>Gómez-Gallego, Carlos</creatorcontrib><title>Safety of Novel Microbes for Human Consumption: Practical Examples of Assessment in the European Union</title><title>Frontiers in microbiology</title><addtitle>Front Microbiol</addtitle><description>Novel microbes are either newly isolated genera and species from natural sources or bacterial strains derived from existing bacteria. Novel microbes are gaining increasing attention for the general aims to preserve and modify foods and to modulate gut microbiota. The use of novel microbes to improve health outcomes is of particular interest because growing evidence points to the importance of gut microbiota in human health. As well, some recently isolated microorganisms have promise for use as probiotics, although in-depth assessment of their safety is necessary. Recent examples of microorganisms calling for more detailed evaluation include , fructophilic lactic acid bacteria (FLAB), and . This paper discusses each candidate's safety evaluation for novel food or novel food ingredient approval according to European Union (EU) regulations. The factors evaluated include their beneficial properties, antibiotic resistance profiling, history of safe use (if available), publication of the genomic sequence, toxicological studies in agreement with novel food regulations, and the qualified presumptions of safety. Sufficient evidences have made possible to support and authorize the use of heat-inactivated in the European Union. In the case of , the discussion focuses on earlier safety studies and the strain's suitability. FLAB are also subjected to standard safety assessments, which, along with their proximity to lactic acid bacteria generally considered to be safe, may lead to novel food authorization in the future. Further research with will increase knowledge about its safety and probiotic properties and may lead to its future use as novel food. Upcoming changes in EUU Regulation 2015/2283 on novel food will facilitate the authorization of future novel products and might increase the presence of novel microbes in the food market.</description><subject>Akkermansia muciniphila</subject><subject>Bacteroides xylanisolvens</subject><subject>Faecalibacterium prausnitzii</subject><subject>fructophilic lactic acid bacteria</subject><subject>Fructophilic lactic acid bacteria, Faecalibacterium prausnitzii</subject><subject>Microbiology</subject><subject>Novel microbes</subject><subject>Safety</subject><issn>1664-302X</issn><issn>1664-302X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVUk1r3DAQNaWlCWnuPRUde9mtPizLyqEQlk0TSNJCG-hNSPJ4oyBLrmQnzb-vdjcNyYBmBmnemwd6VfWR4CVjrfzSD86aJcVELMuh_E11SJqmXjBMf7990R9Uxznf4RI1piW_rw5oKzlnhBxW_U_dw_SIYo-u4z14dOVsigYy6mNC5_OgA1rFkOdhnFwMJ-hH0nZyVnu0_quH0ZfJgj3NGXIeIEzIBTTdAlrPKY5Q0Deh4D5U73rtMxw_1aPq5mz9a3W-uPz-7WJ1ermwXMhpIThwYk3fm461oi4asbBcUitxbbumFV0vLCXS1EBaLYAxZhjuMOmgoW3pj6qLPW8X9Z0akxt0elRRO7W7iGmjdCryPSgqOwu2tSAkq0WLW0OpNYRqoF3NuCxcJ3uuB72B4EJJKuhkXd4RemfSlvxhTir4bRlnkxWngu_AX_fgcjlA2RSmpP0rRa9fgrtVm3iveIMJbupC8PmJIMU_M-RJDS5b8F4HiHNWRNYlsORNGcX70fJzOSfon9cQrLZWUTurqK1V1M4qBfLppbxnwH9jsH834r2O</recordid><startdate>20170912</startdate><enddate>20170912</enddate><creator>Brodmann, Theodor</creator><creator>Endo, Akihito</creator><creator>Gueimonde, Miguel</creator><creator>Vinderola, Gabriel</creator><creator>Kneifel, Wolfgang</creator><creator>de Vos, Willem M</creator><creator>Salminen, Seppo</creator><creator>Gómez-Gallego, Carlos</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>QVL</scope><scope>DOA</scope></search><sort><creationdate>20170912</creationdate><title>Safety of Novel Microbes for Human Consumption: Practical Examples of Assessment in the European Union</title><author>Brodmann, Theodor ; Endo, Akihito ; Gueimonde, Miguel ; Vinderola, Gabriel ; Kneifel, Wolfgang ; de Vos, Willem M ; Salminen, Seppo ; Gómez-Gallego, Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c579t-75e51cbffbd387455307c592c904cd687df7c219b4e18a7e333b30d01de6283b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Akkermansia muciniphila</topic><topic>Bacteroides xylanisolvens</topic><topic>Faecalibacterium prausnitzii</topic><topic>fructophilic lactic acid bacteria</topic><topic>Fructophilic lactic acid bacteria, Faecalibacterium prausnitzii</topic><topic>Microbiology</topic><topic>Novel microbes</topic><topic>Safety</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brodmann, Theodor</creatorcontrib><creatorcontrib>Endo, Akihito</creatorcontrib><creatorcontrib>Gueimonde, Miguel</creatorcontrib><creatorcontrib>Vinderola, Gabriel</creatorcontrib><creatorcontrib>Kneifel, Wolfgang</creatorcontrib><creatorcontrib>de Vos, Willem M</creatorcontrib><creatorcontrib>Salminen, Seppo</creatorcontrib><creatorcontrib>Gómez-Gallego, Carlos</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>NARCIS:Publications</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brodmann, Theodor</au><au>Endo, Akihito</au><au>Gueimonde, Miguel</au><au>Vinderola, Gabriel</au><au>Kneifel, Wolfgang</au><au>de Vos, Willem M</au><au>Salminen, Seppo</au><au>Gómez-Gallego, Carlos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of Novel Microbes for Human Consumption: Practical Examples of Assessment in the European Union</atitle><jtitle>Frontiers in microbiology</jtitle><addtitle>Front Microbiol</addtitle><date>2017-09-12</date><risdate>2017</risdate><volume>8</volume><spage>1725</spage><epage>1725</epage><pages>1725-1725</pages><issn>1664-302X</issn><eissn>1664-302X</eissn><abstract>Novel microbes are either newly isolated genera and species from natural sources or bacterial strains derived from existing bacteria. Novel microbes are gaining increasing attention for the general aims to preserve and modify foods and to modulate gut microbiota. The use of novel microbes to improve health outcomes is of particular interest because growing evidence points to the importance of gut microbiota in human health. As well, some recently isolated microorganisms have promise for use as probiotics, although in-depth assessment of their safety is necessary. Recent examples of microorganisms calling for more detailed evaluation include , fructophilic lactic acid bacteria (FLAB), and . This paper discusses each candidate's safety evaluation for novel food or novel food ingredient approval according to European Union (EU) regulations. The factors evaluated include their beneficial properties, antibiotic resistance profiling, history of safe use (if available), publication of the genomic sequence, toxicological studies in agreement with novel food regulations, and the qualified presumptions of safety. Sufficient evidences have made possible to support and authorize the use of heat-inactivated in the European Union. In the case of , the discussion focuses on earlier safety studies and the strain's suitability. FLAB are also subjected to standard safety assessments, which, along with their proximity to lactic acid bacteria generally considered to be safe, may lead to novel food authorization in the future. Further research with will increase knowledge about its safety and probiotic properties and may lead to its future use as novel food. Upcoming changes in EUU Regulation 2015/2283 on novel food will facilitate the authorization of future novel products and might increase the presence of novel microbes in the food market.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>28955311</pmid><doi>10.3389/fmicb.2017.01725</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-302X
ispartof Frontiers in microbiology, 2017-09, Vol.8, p.1725-1725
issn 1664-302X
1664-302X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_29dcec8ce79347808b22cb12ae2d4359
source Open Access: PubMed Central
subjects Akkermansia muciniphila
Bacteroides xylanisolvens
Faecalibacterium prausnitzii
fructophilic lactic acid bacteria
Fructophilic lactic acid bacteria, Faecalibacterium prausnitzii
Microbiology
Novel microbes
Safety
title Safety of Novel Microbes for Human Consumption: Practical Examples of Assessment in the European Union
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T06%3A18%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20Novel%20Microbes%20for%20Human%20Consumption:%20Practical%20Examples%20of%20Assessment%20in%20the%20European%20Union&rft.jtitle=Frontiers%20in%20microbiology&rft.au=Brodmann,%20Theodor&rft.date=2017-09-12&rft.volume=8&rft.spage=1725&rft.epage=1725&rft.pages=1725-1725&rft.issn=1664-302X&rft.eissn=1664-302X&rft_id=info:doi/10.3389/fmicb.2017.01725&rft_dat=%3Cproquest_doaj_%3E1944440956%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c579t-75e51cbffbd387455307c592c904cd687df7c219b4e18a7e333b30d01de6283b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1944440956&rft_id=info:pmid/28955311&rfr_iscdi=true